Healthcare Ai Exits Pilot Phase, Enters Production Deployment

What Happened?

Shares of health insurance company Oscar Health jumped 4% in the morning session after Stephens & Co. initiated coverage on the stock with an "Equal-Weight" rating and a $17 price target. 

While an "Equal-Weight" rating suggests the stock was expected to perform in line with the sector, the start of coverage itself can be viewed positively as it brings more analyst attention to the company. The move also followed a recent upgrade from another firm. In late November, Piper Sandler raised its rating on Oscar Health to "Overweight" from "Neutral" and increased its price target to $25 from $13. At the time, Piper Sandler's analyst expressed confidence that the company could grow its market share and profitability.

After the initial pop the shares cooled down to $16.31, up 4.1% from previous close.

Is now the time to buy Oscar Health? Access our full analysis report here.

What Is The Market Telling Us

Oscar Health’s shares are extremely volatile and have had 61 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 10 days ago when the stock dropped 6% on the news that investor concerns over rising medical costs and the expiration of healthcare subsidies fueled bearish market activity. 

The negative sentiment was reflected in the options market, where there was a higher demand for bets that the stock price would fall. This pressure came from fundamental challenges facing the company. Oscar Health, like other insurers, experienced a rise in its medical loss ratio because of increased use of services by its members. This trend contributed to the company posting a quarterly operating loss of around $129 million. Furthermore, the expiration of pandemic-era subsidies for individuals was expected to reduce the number of people paying for insurance, potentially leading to fewer customers for Oscar Health in the future.

Oscar Health is up 20.3% since the beginning of the year, but at $16.31 per share, it is still trading 27.4% below its 52-week high of $22.47 from October 2025. Investors who bought $1,000 worth of Oscar Health’s shares at the IPO in March 2021 would now be looking at an investment worth $468.53.

What Happened?

Shares of biotech company 10x Genomics fell 6.3% in the morning session after Citigroup downgraded the stock to Neutral from Buy. 

The analyst firm adjusted its rating on the life science tools and diagnostics company, signaling a less optimistic outlook on its near-term performance. While Citigroup kept its price target for 10x Genomics unchanged at $18, the downgrade from a "Buy" rating was the key factor influencing investor sentiment. Such a change from an analyst can often lead investors to reconsider their position in a stock.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy 10x Genomics? Access our full analysis report here.

What Is The Market Telling Us

10x Genomics’s shares are extremely volatile and have had 50 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 17 days ago when the stock gained 8.2% on the news that reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. 

These subsidies, which are government financial aids to help people pay for health insurance, are crucial for insurers as they maintain a stable customer base. An extension would ensure continued revenue for companies with significant exposure to the ACA marketplace. The news prompted a strong positive reaction from investors, with Centene (CNC) shares jumping as much as 8%, Molina Healthcare (MOH) rising over 3%, and Oscar Health (OSCR) soaring 18%. The potential for a two-year extension reduces regulatory uncertainty for the sector, which investors view as a significant positive for the industry's outlook.

10x Genomics is up 16.3% since the beginning of the year, but at $16.51 per share, it is still trading 18% below its 52-week high of $20.13 from November 2025. Investors who bought $1,000 worth of 10x Genomics’s shares 5 years ago would now be looking at an investment worth $111.59.